StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.85+0.41 (+1.49%)

Close on Nov 17, 2026Market cap $4.83BP/E –Yield –

Cogent Biosciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Cogent Biosciences's price to sales ratio was 35.7× on Apr 30, 2021, against 0.6× a year earlier. Over the last 3 years it ranged from 0.5× to 58.4×, with a median of 7.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2021Apr 30, 202135.7×+30.5
2020Dec 31, 20205.2×+3.2
2019Dec 31, 20192.0×−14.3
2018Dec 31, 201816.4×–

More Cogent Biosciences figures

See a number that looks wrong?